← Leaderboards
Xiaohui Liu
Kuda Therapeutics, Inc.
$355,000
Attributed
$355,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2018–19$500K$375K$250K$125K$0
'18
'19
Funding mix
By agency
NIH$355,000 · 1
By mechanism
R43$355,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Kuda Therapeutics, Inc.
Same institution · by research overlap
- Robert Lippert$2,050,000
Others in their field
Other Emerging Leaders on “Inhibitor/Antagonist”
- Susan Abushakra · Alzheon, Inc.$27,500,000
- Alan D. Palkowitz · Indiana University Indianapolis$10,342,358
- Michael-Christopher Keogh · Epicypher, Inc.$6,845,336
- Terry Roemer · Prokaryotics, Inc.$6,530,728
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$6,175,581
- Aaron Esser-Kahn · University Of Chicago$5,799,408
Research focus
Inhibitor/AntagonistIn VivoFerritinHypoxia Inducible FactorBindingIn VitroAffectElementsGrowthHigh Throughput ScreeningCell TypeCharacteristics5&AposChemotherapyClear CellBiomarker ValidationBaseDrug ResistanceBhlh-Pas Factor HlfGenetic TranscriptionCell GrowthHepatotoxicityDoseIron
Grant awards (3)
Development of a novel class of selective HIF-2A inhibitors for kidney cancer$55,000
R43 · FY2019 · CA · contact PI
Development of a novel class of selective HIF-2A inhibitors for kidney cancer$180,074
R43 · FY2018 · CA · contact PI
Development of a novel class of selective HIF-2A inhibitors for kidney cancer$119,926
R43 · FY2018 · CA · contact PI